CurrentBlue Cross Blue Shield - MassachusettsPolicy 702

Serum biomarker panel testing for systemic lupus erythematosus and other connective tissue diseases

This policy governs coverage of proprietary serum biomarker panel tests with algorithmic/index scores for diagnosing systemic lupus erythematosus (SLE) and other connective tissue diseases for Blue Cross Blue Shield of Massachusetts members.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicySerum biomarker panel testing for systemic lupus erythematosus and other connective tissue diseases

Policy CodePolicy 702

Change TypeNo material change

Effective Date

Next Review Date

Key ActionObtain precertification/preauthorization when the service is performed inpatient; outpatient services described are not a covered benefit for multiple product types.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

InvestigationalCoverage stance

0062U, 0312UListed codes

RequiredPrior auth

2.04.123Internal ref

Coverage Criteria and Policy Statement

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Investigational / Not covered as medically necessary

Covered when ALL of the following are met:

Policy coverage stance: Serum biomarker panel testing with proprietary algorithms and/or index scores for the diagnosis of systemic lupus erythematosus and other connective tissue diseases is considered investigational.

Applies to Commercial Members and Medicare products as described.

Evidence summary: Evidence includes diagnostic accuracy studies and one prospective evaluation of clinical utility; evidence is insufficient to demonstrate improvement in net health outcome for SLE or other CTDs.

Observational studies were primarily retrospective, not performed in the intended-use population and lacked appropriate comparators; the single RCT measured change in physician global assessment, which is not a patient health outcome.

This policy applies to Blue Cross Blue Shield of Massachusetts members, including Commercial Members (Managed Care HMO and POS, PPO, and Indemnity) and Medicare HMO BlueSM and Medicare PPO BlueSM Members. It governs coverage of proprietary serum biomarker panel tests with algorithmic or index scores when used for the diagnosis of systemic lupus erythematosus (SLE) and other connective tissue diseases.

Per the policy, serum biomarker panel testing with proprietary algorithms/index scores for SLE and other CTDs is considered investigational, and outpatient use of these services is listed as not a covered service for multiple product types. Precertification/preauthorization requirements apply as described in the policy.

Serum biomarker panel testing that incorporates proprietary algorithms and/or index scores to assess likelihood of systemic lupus erythematosus or other connective tissue diseases is investigational and therefore not medically necessary under this policy.

Coding and Billing Codes

Included CPT Codes (investigational designation stated)CPT

0062U	Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80.
0312U	Autoimmune diseases (eg, systemic lupus erythematosus [SLE]), analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using enzyme-linked immunoassay (ELISA); flow cytometry and indirect reported along with an algorithmic SLE-likelihood assessment

Provider Responsibilities and Authorization

Denial Risk

Investigational — Triggers Noncoverage

Serum biomarker panel testing with proprietary algorithms and/or index scores for diagnosis of systemic lupus erythematosus and other connective tissue diseases is considered investigational and therefore non-covered for the products listed below. Providers should not expect reimbursement for investigational services and may receive a denial (noncoverage) if submitted.

Applies to Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity; Medicare HMO BlueSM and Medicare PPO BlueSM.

Prior Authorization

Prior Authorization Required (Inpatient) / Outpatient Not Covered

Precertification/preauthorization is required when the procedure is performed inpatient. For outpatient services described in this policy, the listed products indicate the service is not covered and prior authorization would not make the service covered.

Inpatient: Prior authorization required for all products if procedure is inpatient.
Outpatient: Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO BlueSM, Medicare PPO BlueSM — outpatient services are not covered.

Documentation Required

Coding and Documentation Guidance

Providers must report all services using current procedure, revenue, and diagnosis codes and include applicable modifiers. Coding inclusion in this policy is informational and does not guarantee coverage; always verify member contract benefits for coverage determination.

Use current CPT/HCPCS/ICD-10 codes and modifiers.
The CPT code(s) listed in the policy are informational only; inclusion may be labeled investigational for Commercial Members.

Step Therapy

There are no step therapy requirements for the services described in this policy.

Background and Context

Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disease that can affect multiple organ systems and is frequently challenging to diagnose because symptoms overlap with other connective tissue diseases. Proprietary multianalyte serum biomarker panels with algorithmic scores have been developed to aid diagnosis, but the policy concludes that current evidence is insufficient to demonstrate an improvement in net health outcome for SLE or other CTDs.

Because these proprietary panels are considered investigational, the policy specifies administrative controls: precertification/preauthorization is required when the procedure is performed inpatient, and outpatient performance of the services is identified as not a covered service for Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO BlueSM, and Medicare PPO BlueSM.

Key Definitions

Systemic lupus erythematosus (SLE) — definition/key features

DefinitionSystemic lupus erythematosus (SLE) is an autoimmune connective tissue disease that can cause inflammation and affect multiple organ systems (skin, heart, joints, lungs, blood vessels, liver, kidneys, nervous system).

EpidemiologyApproximately 90% of lupus patients are women aged 15–44 years.

Clinical impactSLE increases morbidity and mortality (eg, cardiovascular disease from accelerated atherosclerosis), can lead to kidney failure, and is associated with infections, cancer, avascular necrosis, and pregnancy complications such as preeclampsia and preterm birth.

CourseThe disease course is variable; symptoms like joint and muscle pain can substantially affect quality of life and functional status.

Connective tissue diseases (CTDs) — definition and examples

DefinitionConnective tissue diseases (CTDs) are autoimmune disorders that may require differential diagnosis from SLE and include conditions affecting joints, muscles, skin, glands, and other organs.

ExamplesRheumatoid arthritis — chronic inflammatory peripheral polyarthritis that can affect skin, eyes, lungs, heart, and blood vessels.

ExamplesThyroid autoimmune diseases — Graves disease (causes hyperthyroidism via TSH receptor antibodies) and Hashimoto disease (chronic lymphocytic thyroiditis causing hypothyroidism).

ExamplesSjogren syndrome — autoimmune disorder causing dryness of eyes and mouth with typical antibodies (ANA, anti-SSA, anti-SSB, rheumatoid factor).

ExamplesAntiphospholipid syndrome — systemic autoimmune disorder characterized by venous or arterial thrombosis and/or pregnancy morbidity due to antiphospholipid antibodies.

ExamplesPolymyositis and dermatomyositis — inflammatory myopathies causing muscle weakness; dermatomyositis may have skin manifestations.